For the year ending 2025-12-31, TBPH has $485,570K in assets. $167,806K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 167,806 | |||
| Short-term marketable securities | 147,551 | |||
| Receivables from collaborative arrangements | 45,539 | |||
| Receivables from milestones and royalty assets | 50,000 | |||
| Other prepaid and current assets | 7,564 | |||
| Total current assets | 418,460 | |||
| Long-term marketable securities | 11,128 | |||
| Property and equipment, net | 5,895 | |||
| Operating lease assets | 24,371 | |||
| Restricted cash | 836 | |||
| Other assets | 24,880 | |||
| Total assets | 485,570 | |||
| Accounts payable | 2,568 | |||
| Accrued personnel-related expenses | 12,592 | |||
| Accrued clinical and development expenses | 3,373 | |||
| Accrued general and administrative expenses | 2,052 | |||
| Operating lease liabilities | 10,945 | |||
| Income tax payable | 5,287 | |||
| Other accrued liabilities | 1,485 | |||
| Total current liabilities | 38,302 | |||
| Long-term operating lease liabilities | 31,758 | |||
| Future royalty payment contingency | 32,795 | |||
| Unrecognized tax benefits | 85,679 | |||
| Other long-term liabilities | 313 | |||
| Ordinary shares, 0.00001 par value per share 200,000 shares authorized 51,069 and 49,471 shares issued and outstanding at december 31, 2025 and december 31, 2024, respectively | 1 | |||
| Additional paid-in capital | 1,156,288 | |||
| Accumulated other comprehensive income | 61 | |||
| Accumulated deficit | -859,627 | |||
| Total shareholders' equity | 296,723 | |||
| Total liabilities and shareholders' equity | 485,570 | |||
Theravance Biopharma, Inc. (TBPH)
Theravance Biopharma, Inc. (TBPH)